The therapeutic potential of AN-7, a novel histone deacetylase inhibitor, for treatment of mycosis fungoides/sezary syndrome alone or with doxorubicin

Lilach Moyal, Nataly Feldbaum, Neta Goldfeiz, Ada Rephaeli, Abraham Nudelman, Michal Weitman, Nataly Tarasenko, Batia Gorovitz, Leah Maron, Shiran Yehezkel, Iris Amitay-Laish, Ido Lubin, Emmilia Hodak

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous Tcell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of overall response and high rates of adverse effects. Data regarding combination treatments with HDACIs is sparse. Butyroyloxymethyl diethylphosphate (AN-7) is a novel HDACI, which was found to have selective anticancer activity in several cell lines and animal models. The aim of this study was to compare the anticancer effects of AN-7 and SAHA, either alone or combined with doxorubicin, on MF/SS cell lines and peripheral blood lymphocytes (PBL) from patients with Sezary syndrome (SPBL). MyLa cells, Hut78 cells, SPBL, and PBL from healthy normal individuals (NPBL) were exposed to the test drugs, and the findings were analyzed by a viability assay, an apoptosis assay, and Western blot. AN-7 was more selectively toxic to MyLa cells, Hut78 cells, and SPBL (relative to NPBL) than SAHA and also acted more rapidly. Both drugs induced apoptosis in MF/SS cell lines, SAHA had a greater effect on MyLa cell line, while AN-7 induced greater apoptosis in SPBL; both caused an accumulation of acetylated histone H3, but AN-7 was associated with earlier kinetics; and both caused a downregulation of the HDAC1 protein in MF/SS cell lines. AN-7 acted synergistically with doxorubicin in both MF/SS cell lines and SPBL, and antagonistically with doxorubicin in NPBL. By contrast, SAHA acted antagonistically with doxorubicin on MF/SS cell lines, SPBL, and NPBL, leaving >50% viable cells. In conclusion, AN-7 holds promise as a therapeutic agent in MF/SS and has several advantages over SAHA. Our data providea rationale for combining AN-7, but not SAHA, with doxorubicin to induce the cell death in MF/SS.

Original languageEnglish
Article numbere0146115
JournalPLoS ONE
Issue number1
StatePublished - 11 Jan 2016

Bibliographical note

Funding Information:
This study was funded in part by the Israel Cancer Association and by the Bar Ilan University and Rabin Medical Center Collaboration in Biomedical Research.

Publisher Copyright:
Copyright © 2016 Moyal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Dive into the research topics of 'The therapeutic potential of AN-7, a novel histone deacetylase inhibitor, for treatment of mycosis fungoides/sezary syndrome alone or with doxorubicin'. Together they form a unique fingerprint.

Cite this